430 related articles for article (PubMed ID: 20730629)
21. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the biochemistry of sphingolipidoses.
Kolter T; Sandhoff K
Brain Pathol; 1998 Jan; 8(1):79-100. PubMed ID: 9458169
[TBL] [Abstract][Full Text] [Related]
23. Future perspectives for glycolipid research in medicine.
Cox TM
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):967-73. PubMed ID: 12803931
[TBL] [Abstract][Full Text] [Related]
24. Use of BODIPY-labeled sphingolipids to study membrane traffic along the endocytic pathway.
Pagano RE; Chen CS
Ann N Y Acad Sci; 1998 Jun; 845():152-60. PubMed ID: 9668349
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases.
Seranova E; Connolly KJ; Zatyka M; Rosenstock TR; Barrett T; Tuxworth RI; Sarkar S
Essays Biochem; 2017 Dec; 61(6):733-749. PubMed ID: 29233882
[TBL] [Abstract][Full Text] [Related]
26. Niemann-Pick type C disease: The atypical sphingolipidosis.
Newton J; Milstien S; Spiegel S
Adv Biol Regul; 2018 Dec; 70():82-88. PubMed ID: 30205942
[TBL] [Abstract][Full Text] [Related]
27. Sphingolipid metabolism diseases.
Kolter T; Sandhoff K
Biochim Biophys Acta; 2006 Dec; 1758(12):2057-79. PubMed ID: 16854371
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy: prospects for glycolipid storage diseases.
Gieselmann V; Matzner U; Klein D; Mansson JE; D'Hooge R; DeDeyn PD; Lüllmann Rauch R; Hartmann D; Harzer K
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):921-5. PubMed ID: 12803926
[TBL] [Abstract][Full Text] [Related]
29. Gene Therapy of Sphingolipid Metabolic Disorders.
Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
[TBL] [Abstract][Full Text] [Related]
30. A historical perspective of the glycosphingolipids and sphingolipidoses.
Watts RW
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):975-83. PubMed ID: 12803932
[TBL] [Abstract][Full Text] [Related]
31. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell.
Sandhoff K; Kolter T; Van Echten-Deckert G
Ann N Y Acad Sci; 1998 Jun; 845():139-51. PubMed ID: 9668348
[TBL] [Abstract][Full Text] [Related]
32. Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy.
Santos R; Amaral O
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771289
[TBL] [Abstract][Full Text] [Related]
33. Membrane traffic in sphingolipid storage diseases.
Pagano RE; Puri V; Dominguez M; Marks DL
Traffic; 2000 Nov; 1(11):807-15. PubMed ID: 11208071
[TBL] [Abstract][Full Text] [Related]
34. Storage diseases: new insights into sphingolipid functions.
Sillence DJ; Platt FM
Trends Cell Biol; 2003 Apr; 13(4):195-203. PubMed ID: 12667757
[TBL] [Abstract][Full Text] [Related]
35. From sheep to mice to cells: tools for the study of the sphingolipidoses.
Zigdon H; Meshcheriakova A; Futerman AH
Biochim Biophys Acta; 2014 Aug; 1841(8):1189-99. PubMed ID: 24607565
[TBL] [Abstract][Full Text] [Related]
36. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
Haneef SA; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
[TBL] [Abstract][Full Text] [Related]
37. Zebra-Sphinx: Modeling Sphingolipidoses in Zebrafish.
Mignani L; Guerra J; Corli M; Capoferri D; Presta M
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902174
[TBL] [Abstract][Full Text] [Related]
38. Synaptic failure: The achilles tendon of sphingolipidoses.
Cantuti-Castelvetri L; Bongarzone ER
J Neurosci Res; 2016 Nov; 94(11):1031-6. PubMed ID: 27638588
[TBL] [Abstract][Full Text] [Related]
39. Sphingolipid lysosomal storage diseases: from bench to bedside.
Abed Rabbo M; Khodour Y; Kaguni LS; Stiban J
Lipids Health Dis; 2021 May; 20(1):44. PubMed ID: 33941173
[TBL] [Abstract][Full Text] [Related]
40. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.
Kirkegaard T; Gray J; Priestman DA; Wallom KL; Atkins J; Olsen OD; Klein A; Drndarski S; Petersen NH; Ingemann L; Smith DA; Morris L; Bornæs C; Jørgensen SH; Williams I; Hinsby A; Arenz C; Begley D; Jäättelä M; Platt FM
Sci Transl Med; 2016 Sep; 8(355):355ra118. PubMed ID: 27605553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
